Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

People with diabetes in the United Kingdom, Ireland, Germany, Austria and Hong Kong can get started with Dexcom G7 now The new CGM system is also expected to launch in […]

McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group

Transaction enhances McKesson’s focus and commitment to future investments in strategic growth, including oncology and biopharma services, and core pharmaceutical and medical distribution Agreement includes the sale of McKesson Europe […]

New Data from KEYNOTE-028, MSD’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress

MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to MSD’s growing body of clinical data for KEYTRUDA.

New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma

MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose tumors express PD-L1 (≥1% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801).

MSDs Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

MSD, known as Merck (NYSE:MRK) in the United States and Canada, announced today the first presentations of data from the companys ongoing C-EDGE pivotal Phase 3 clinical trial programme evaluating the investigational once-daily tablet grazoprevir/elbasvir (100mg/50mg) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6).1 Patients in both the HCV infected, treatment-naïve (C-EDGE TN), and HIV/HCV co-infected, treatment-naïve (C-EDGE CO-INFXN) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299/316 and 207/218, respectively). In addition, HCV infected, treatment-experienced patients (C-EDGE TE) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98/104) and 92 percent (97/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103/106) and 92 percent (97/105), respectively. These data were presented at The International Liver CongressTM 2015 the 50th annual congress of the European Association for the Study of the Liver (Abstract #G07, E-Poster P0886 and E-Poster P0887). A paper detailing the findings of C-EDGE TN was published online in the Annals of Internal Medicine today.

MSD Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the first presentation of data from C-SURFER, the companys Phase 2/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1).1 Treatment-naïve patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had CKD stages 4 or 5, were enrolled.2 Following 12 weeks of treatment with grazoprevir and elbasvir, 99 percent (115/116) of patients in the pre-specified primary population for analysis of efficacy data achieved a sustained virologic response 12 weeks after the completion of treatment (SVR12).3 These data will be presented today at The International Liver CongressTM 2015 the 50th annual congress of the European Association for the Study of the Liver (late breaking E-Poster #LP02).

Victorias Secret and Swarovski Sparkled at Their London Debut

For nearly 120 years, Swarovski has inspired creative talents from the world of fashion, jewelry, accessories, interior design and lighting with its brilliant crystal innovations. It seeks to push the boundaries of creativity and to bring the sparkling glamour of crystal to designer and consumer alike. Since 2002, Swarovski has exclusively provided dazzling crystals to adorn costumes and jewelry of the most glamorous events on the fashion calendar, including the Victorias Secret Fashion Show. This celebrated catwalk extravaganza is where lingerie, and couture meet, as the world’s most beautiful modelsknown as Victorias Secret Angelsblaze a trail down the runway.

New Study Shows Magnetic Implant is an Important Break-Through in the Treatment of Reflux Disease

Torax Medical announced today the publication of new data comparing the LINX Magnetic Sphincter Augmentation Device and laparoscopic fundoplication surgery in 249 patients. Data from this study significantly adds to the growing body of evidence that the LINX device is a safe and effective procedure for patients suffering from gastro-esophageal reflux disease (GERD). Current surgical options (fundoplication) require the patients stomach tissue to be wrapped around the esophagus to create a barrier to reflux. The LINX device provides protection from reflux without compromising the patients stomach while minimizing the side effects commonly associated with the present surgical approaches.

MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

MSD, known as Merck & Co., Inc. (NYSE:MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, MSDs investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to MSDs once-daily DPP-4 inhibitor, JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan.1 MSD presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting.

ToysRUs, Inc. Strengthens Global E-Commerce Presence with Launch of Dedicated Web Store in China, Mobile Shopping Capabilities Introduced in Additional International Markets

ToysRUs, Inc. today announced it has strengthened its global e-commerce capabilities with the launch of a dedicated web store,, in China. The addition of this site represents a significant step in the companys plans to grow its presence with physical stores and online operations in Asia. The company has also announced the development of mobile-optimized sites and apps in 11 markets around the world, including Australia, Canada, France, Germany, Japan, Spain, and the U.K. In the coming months, it will introduce the same capabilities in Portugal, Austria and Switzerland, as well as the Netherlands, where it does not currently have a store presence.